Opendata, web and dolomites

RHYP SIGNED

A new hope for early gonarthrosis treatment using a biotechnological therapeutic drug to regenerate cartilage by intra-articular knee injection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RHYP project word cloud

Explore the words cloud of the RHYP project. It provides you a very rough idea of what is the project "RHYP" about.

mrd    action    stage    commercialization    licensees    acid    conditioning    burden    mainly    ambition    cartilage    gonarthrosis    trl    function    stop    molecules    obese    batch    symptomatic    human    disruptive    contribution    vivo    syringes    slow    drug    launching    economic    local    75    athletes    prepare    sme    surgery    pushing    market    organization    tackle    proof    progression    feasibility    conduct    injection    younger    drawback    degradation    global    viscosupplementation    first    candidate    successful    restore    chondrocytes    treatment    health    disease    articulation    thanks    gap    03    activation    smeinst    knee    painless    plug    proliferation    responding    curative    reg    2017    social    suffer    huge    gmp    worldwide    trial    2016    moderate    degenerative    clinical    50    rhyp    24    partnership    treatments    ga    manufacturing    requested    previously    2014    vitro    price       instrument    replacement    competitive    people    trials    months    administration    o3    joint    sustain    countries    clinics    world    hyaluronic    450    ec    total    mode    therapeutic   

Project "RHYP" data sheet

The following table provides information about the project.

Coordinator
REGULAXIS 

Organization address
address: 102 AVENUE GASTON ROUSSEL
city: ROMAINVILLE
postcode: 93230
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://regulaxis.com/
 Total cost 3˙008˙500 €
 EC max contribution 2˙105˙950 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGULAXIS FR (ROMAINVILLE) coordinator 2˙105˙950.00

Map

 Project objective

The aim of RHYP is to sustain the commercialization of a new promising therapeutic product (REG-O3) to restore the joint function for the treatment of early and moderate gonarthrosis (GA). GA is a degenerative knee joint disease that represents a huge social and economic burden worldwide. According to the World Health Organization, more than 5% of people over 40 and 50% of people over 75 years suffer specifically from GA in developed countries. It affects also a growing number of younger people as athletes and obese people, among others. There are currently no therapeutic molecules on the market for the treatment of early GA to slow down or stop disease progression and avoid surgery joint replacement. Available treatments for this disease stage are mainly symptomatic, such as the widely use injection of hyaluronic acid (HA) in articulation (viscosupplementation – Global market €1.5 Mrd in 2014). RHYP’s ambition is to tackle this current drawback by pushing forward its drug candidate REG-O3 into clinics to propose a disruptive and long-term treatment (curative and symptomatic action) using a painless local administration mode at a competitive price (€450 for total treatment is estimated). The selected lead REG-O3 activity proof of concept on chondrocytes proliferation activation to slow down cartilage degradation was previously established in vitro and in vivo. Following successful feasibility studies conducted thanks to the European commission (EC) through the Phase 1 of the SME Instrument, RHYP is now responding to the topic “SMEInst-03-2016-2017” in phase 2. RHYP is now aiming, during this 24 months’ project with a EC requested contribution of €2,1 M, to plug the gap from TRL 6 to TRL 9 by launching REG-O3 GMP batch manufacturing and syringes conditioning to conduct First-in-Human clinical trial. The project objective is also to prepare future partnership with identified potential licensees to conduct Clinical trials in Phase III and drug commercialization.

 Deliverables

List of deliverables.
Ethical protocols reports and authorization approval copies Documents, reports 2020-04-16 13:45:11
Report to present RHYP corporate identity and first leaflet and promotion material models Documents, reports 2020-01-21 15:58:55

Take a look to the deliverables list in detail:  detailed list of RHYP deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHYP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHYP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More  

SINUSLIGHT (2018)

Laser-spectroscopic sensing device for diagnostic assessment of sinusitis

Read More